These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 31419575)

  • 21. Fecal immunochemical testing results and characteristics of colonic lesions.
    van Doorn SC; Stegeman I; Stroobants AK; Mundt MW; de Wijkerslooth TR; Fockens P; Kuipers EJ; Bossuyt PM; Dekker E
    Endoscopy; 2015 Nov; 47(11):1011-7. PubMed ID: 26126163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple Negative Fecal Immunochemical Tests Reduce Risk of Advanced Neoplasia in a Colonoscopy Surveillance Program.
    Wassie MM; Young GP; Winter JM; Cock C; Bampton P; Rahman M; Heddle R; Fraser R; Meng R; Symonds EL
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2389-2398.e2. PubMed ID: 36610499
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term performance of colorectal cancerscreening programmes based on the faecal immunochemical test.
    Zorzi M; Hassan C; Capodaglio G; Fedato C; Montaguti A; Turrin A; Rosano A; Monetti D; Stocco C; Baracco S; Russo F; Repici A; Rugge M
    Gut; 2018 Dec; 67(12):2124-2130. PubMed ID: 29101260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Colonoscopic screening of average-risk women for colorectal neoplasia.
    Schoenfeld P; Cash B; Flood A; Dobhan R; Eastone J; Coyle W; Kikendall JW; Kim HM; Weiss DG; Emory T; Schatzkin A; Lieberman D;
    N Engl J Med; 2005 May; 352(20):2061-8. PubMed ID: 15901859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Quarter of Participants With Advanced Neoplasia Have Discordant Results From 2-Sample Fecal Immunochemical Tests for Colorectal Cancer Screening.
    Wieten E; de Klerk CM; Lansdorp-Vogelaar I; Bossuyt PM; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Jul; 18(8):1805-1811.e1. PubMed ID: 31563557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Switching from guaiac to immunochemical faecal occult blood test increases participation and diagnostic yield of colorectal cancer screening.
    Bretagne JF; Piette C; Cosson M; Durand G; Lièvre A
    Dig Liver Dis; 2019 Oct; 51(10):1461-1469. PubMed ID: 31151896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colonoscopy Findings in FIT+ and mt-sDNA+ Patients versus in Colonoscopy-only Patients: New Hampshire Colonoscopy Registry Data.
    Anderson JC; Robinson CM; Hisey W; Limburg PJ; Butterly LF
    Cancer Prev Res (Phila); 2022 Jul; 15(7):455-464. PubMed ID: 35378546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic Accuracy of a Qualitative Fecal Immunochemical Test Varies With Location of Neoplasia But Not Number of Specimens.
    Wong MC; Ching JY; Chan VC; Lam TY; Shum JP; Luk AK; Wong SS; Ng SC; Ng SS; Wu JC; Chan FK; Sung JJ
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1472-9. PubMed ID: 25724708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening.
    Kooyker AI; Toes-Zoutendijk E; Opstal-van Winden AWJ; Spaander MCW; Buskermolen M; van Vuuren HJ; Kuipers EJ; van Kemenade FJ; Ramakers C; Thomeer MGJ; Dekker E; Nagtegaal ID; de Koning HJ; van Leerdam ME; Lansdorp-Vogelaar I
    Int J Cancer; 2020 Aug; 147(4):1098-1106. PubMed ID: 31853977
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic Performance of One-off Flexible Sigmoidoscopy with Fecal Immunochemical Testing in a Large Screening Population.
    Niedermaier T; Weigl K; Hoffmeister M; Brenner H
    Epidemiology; 2018 May; 29(3):397-406. PubMed ID: 29287053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flexible sigmoidoscopy following a positive faecal occult blood test within a bowel screening programme may reduce the detection of neoplasia.
    Mansouri D; McMillan DC; Roxburgh CS; Moug SJ; Crighton EM; Horgan PG
    Colorectal Dis; 2013 Nov; 15(11):1375-81. PubMed ID: 23927751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.
    Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
    Gastroenterology; 2017 Jul; 153(1):307-323. PubMed ID: 28600072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adding family history to faecal immunochemical testing increases the detection of advanced neoplasia in a colorectal cancer screening programme.
    Kallenberg FG; Vleugels JL; de Wijkerslooth TR; Stegeman I; Stoop EM; van Leerdam ME; Kuipers EJ; Bossuyt PM; Dekker E
    Aliment Pharmacol Ther; 2016 Jul; 44(1):88-96. PubMed ID: 27170502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
    Gibson DJ; Mooney T; Mooney J; Mulcahy HE; O'Donoghue D
    Gastrointest Endosc; 2019 Mar; 89(3):518-522. PubMed ID: 30142350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults: A Cross-sectional Study.
    Imperiale TF; Monahan PO; Stump TE; Glowinski EA; Ransohoff DF
    Ann Intern Med; 2015 Sep; 163(5):339-46. PubMed ID: 26259154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fecal MicroRNA-Based Algorithm Increases Effectiveness of Fecal Immunochemical Test-Based Screening for Colorectal Cancer.
    Duran-Sanchon S; Moreno L; Gómez-Matas J; Augé JM; Serra-Burriel M; Cuatrecasas M; Moreira L; Serradesanferm A; Pozo À; Grau J; Pellisé M; Gironella M; Castells A
    Clin Gastroenterol Hepatol; 2021 Feb; 19(2):323-330.e1. PubMed ID: 32113893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.